Introduction
Urologic disease within the category of incontinence, including overactive bladder (OAB) and urgency, represents a diverse group of conditions that are often difficult to treat as well as diagnose. Patient histories are often employed as a screening modality 1, 2 and urodynamic testing demonstrating involuntary bladder contraction provides objective confirmation but represents an invasive approach. Furthermore, treatment can be implemented in a trial and error fashion until patient relief is obtained.
In an effort to elucidate biomarkers for incontinence-related diseases toward better understanding the pathophysiology of disease, we have previously demonstrated that peripheral blood mononuclear cells (PBMC) can provide a reporter function in solid organ diseases including pancreatitis and overactive bladder. 3, 4 In those studies, we employed the ability of the immune system to "cross talk" with the affected organ to 
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Cheung et al provide a mirrored reflection of solid organ disease toward biomarker discovery. Since female health issues, such as incontinence and overactive bladder, represent an increasing concern with respect to quality-of-life, psychosocial, and economic dynamics, [5] [6] [7] [8] and treatment modalities and many diagnoses are often based on patient reporting, biomarkers for such disease states are needed for objective diagnosis of urological diseases. Here, we investigated the utility of using PBMC as a biomarker discovery platform for female patients with confirmed involuntary bladder contraction.
Methods

Patient specimens
Peripheral blood (4-5 mL total) was obtained from 15 female patients -average age 51.6 (range 35-63) -with involuntary bladder contractions treated at the Urology Clinic at State University of New York Downstate Medical Center. This study was approved by the Institutional Review Board. All patients completed a validated questionnaire (OAB V8) 1,2,9 for screening of incontinence, and had hallmarks of such including frequency (voiding q2h or more), nocturia 2 or more times at night, and had post void urgency. Further, all patients in this study showed detrusor overactivity during urodynamics and a maximum functional capacity of ,250 mL. All patients had severe frequency, nocturia, and urgency and were objectively assessed for incontinence by video urodynamics. All patients were diagnosed as having urinary incontinence. Patients were also evaluated for involuntary bladder contractions and stress urinary incontinence as demonstrated by urodynamics, pelvic prolapse, stress incontinence by history, bladder neck dysfunction, and bladder capacity as previously reported; 4 bladder neck dysfunction was defined as delayed opening of bladder neck of more than 10 seconds on urodynamics. Blood obtained from three female volunteers (average age 52), served as healthy controls. Patients and controls did not have any history of recent infection or inflammatory disease and were not using immunosuppressing or immunomodulating therapy. Patients with a history of recent surgery, infection, and positive valsalva leak point pressure or negative for involuntary bladder contraction as demonstrated by urodynamics were excluded. All samples were collected before any invasive procedures (urodynamics, surgery). Patient consent for specimens and internal review board approval was obtained.
Blood collection and processing
Blood was collected into EDTA Monoject tubes (Sherwood Medical, St Louis, MO) and retained for up to 2 hours at room temperature. Whole blood was diluted (1:1) with RPMI-1640 (GIBCO BRL Life Technologies, Grand Island, NY) and PBMC were separated from whole blood on FicollPaque (Pharmacia, Uppsala, Sweden) gradients (density, 1.077) in a 1:1 ratio. PBMC were washed twice in Dulbecco's phosphate buffered saline (Sigma-Aldrich, St Louis, MO) (pH 7.4, GIBCO-BRL). Viability was 98%, as judged by trypan blue dye exclusion. 4 Nucleic acid purification and microarray analysis Total RNA was extracted from PBMC, as previously described, 3, 4 using the RNeasy mini kit and eluted using an RNeasy spin column (Qiagen, Inc, Valencia, CA) according to manufacturer's recommendations. RNA quality was assessed on an Agilent 2100 Bioanalyzer, RNA nano 6000 Series II Chips (Agilent, Palo Alto, CA). Samples were assessed by a RIN score; samples with a score of .7.5 were passed and quantity was assessed by Nanodrop ND-1000 (Nanodrop Technologies, Wilmington, DE). Total RNA was amplified by a modified Eberwine technique, using a Message amperes II kit (ABI, Austin, TX). The amplified product was assessed for a normal size distribution using the Agilent 2100 Bioanalyzer RNA 6000 nano Series II Chips. Samples were then prepared for hybridization, hybridized, washed, and scanned according to the manufacturer's instructions on U133A 2.0 GeneChip (Affymetrix, Santa Clara, CA). Affymetrix QC metrics were used to pass the image data. The U133A 2.0 gene chip was based on sequences submitted to the UniGene database (Build 133, April 20, 2001 ) profiling over 18,400 transcripts representing 14,500 well-characterized genes.
statistical analysis
Differential expression analysis was performed using the limma software package from Bioconductor (Seattle, WA). 4, 10 A linear model is fitted to model the systematic part of the data. For statistical analysis, limma uses empiric Bayes method to moderate the standard errors of the estimated logfold change. Patient and differential expression was defined as a change of at least two-fold vs respective controls. The significance level was set at greater than two-fold change among groups (P # 0.05). 
Results
All
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Biomarker discovery in incontinence 51.6 (range 35-66), where most had pelvic prolapse (75%) and stress incontinence by history (63%). Thirty-eight percent of patients had bladder neck dysfunction and all patients had normal to low bladder capacity. Microarray analysis was performed and all genes that were differentially regulated a minimum of two-fold difference from controls were captured (Figure 1 ). Microarray analysis revealed that eleven genes were differentially regulated (five upregulated and six downregulated) (Figure 2 ). Of these, PGRMC1 (progesterone receptor membrane component 1), EIF2S3 (eukaryotic initiation factor), C3AR1 (complement receptor), and three unknown genes were downregulated. Upregulated genes included MYOM2 (myomesin M-protein), a cytoskeletal protein involved in structural integrity. 
Discussion
Women's health-related diseases, including overactive bladder and incontinence, remain a challenge with respect to diagnosis and treatment. Further, the psychosocial aspects of such diseases can often affect quality of life for female patients and promote reclusive behavior and/or depression for fear of embarrassment. 2, [5] [6] [7] [8] The economic burden on the health-care system is also a concern in light of the aging population. 6, 7 Options for disease management can range from therapy to surgical intervention and often vary according to disease presentation and urological comorbidities. 8 Further, medications are often administered empirically and are modified based on patients' subjective responses. Urodynamics testing represents an objective test for diagnosis of incontinence. However, this approach is invasive, costly, requires appropriate skill to perform, and is not available in all health-care clinics. To date there are no diagnostic blood tests for incontinence. As such, a blood-based approach would be very useful for disease diagnosis and response management.
We have previously demonstrated that PBMC can serve a "reporter" function for biomarkers of acute pancreatitis and, as such, could identify unique genes expressed during pancreatitis. 3 In an effort to adapt our leukocyte-based biomarker discovery to human disease, we applied microarray methodology to patients suffering from overactive bladder 4 in those studies PBMC obtained from overactive bladder patients were analyzed. Microarray analysis revealed that 16 genes were differentially regulated (eight upregulated and eight downregulated) in all patients with overactive bladder compared with healthy controls. Furthermore, gender-based analysis demonstrated 74 genes differentially regulated in males (25 upregulated and 49 downregulated), and 30 in females (13 upregulated and 17 downregulated). Of these, PDGF; MFAP3L, a microfibrillar-associated protein; and TPM1 (tropomyosin) were downregulated in all sets analyzed.
Although the use of microarray as a means of elucidating gene changes involved in the pathophysiology of incontinence-type disease have been described, 11, 12 such studies utilize tissues such as vaginal and bladder mucosae for gene array studies. Obtaining these tissues dictates that an invasive approach be taken and would therefore be limited. The ability to adapt this technology to peripheral blood-derived nucleated cells would be ideal in that it would provide a noninvasive, easily accessible approach, without the side effects associated with organ biopsy.
In the current studies, we applied microarray mining methodology to include only female patients with involuntary 
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Cheung et al bladder contractions as a means to focus on women's health-associated disease states with respect to incontinence. As in our previous studies, 4 patients who had evidence of recent infection or immunological modulation, either reported or based on medication history, were excluded to obviate gene changes resulting from inflammatory responses unrelated to their urological disease.
Microarray analysis revealed many genes that were differentially regulated in PBMC from patients with involuntary bladder contractions, including PGRMC1 (progesterone receptor membrane component 1), EIF2S3 (eukaryotic initiation factor), and C3AR1 (complement receptor), which were downregulated. These genes are of note since if their expression were also altered in the bladder and/or its supporting tissues this could result in changes in maintenance of the bladder's structural integrity.
By way of example, PGRMC1 is reported to be involved in sterol metabolism, or homeostasis and cell survival. 13, 14 A recent study by Wu et al 13 has also demonstrated the relationship of PGRMC1 on contraction/relaxation of human myometrium during pregnancy, which suggests its role in maintaining appropriate uterine tone where a decrease in PGRMC1 during term or preterm labor might shift the balance to a state of heightened uterine contractility. EIF23S, which has been shown to regulate the rate of protein translation and escapes X-inactivation in both humans and mice, was found to have increased expression in the brain and liver of females when compared with males. 15 Furthermore, C3AR1, a pleotropic molecule involved in the complement system, also reported as a causal gene for obesity and diabetes, 16, 17 was identified as a causal gene for aortic lesion size in females but not in males and, as such, has been proposed to be involved in altering atherosclerotic lesion susceptibility. 18 Interestingly, C3AR1 was one of the differentially regulated genes identified in stroke patients that employed a similar PBMC-microarray mining approach. 19 To this end, C3AR1 and PGRMC1 also represented genes that were similarly downregulated and PSMD14, KTN1, and AAK1 represented genes that were upregulated only in female patients with overactive bladder where their PBMC were subjected to the same leukocyte-based microarray mining algorithm, 4 further suggesting an involvement of these genes in general female incontinence. Upregulated genes included MYOM2 (myomesin M-protein), which is a member of the M-protein group of cytoskeletal proteins involved in the cross-linking of myofilaments. Although M-proteins have been described in limb and eye muscles, 20, 21 and are probably involved in maintenance of muscular tone, the relationship of MYOM2 to bladder contractility and its role in incontinence remains to be defined.
Furthermore, this approach identified three as of yet unknown genes (NM_014020-LR8, NM_018487-HCA112, AL_049435). Although the function of these expression sequence tags (EST) are unknown, we have found similar elucidation of ESTs in our earlier studies of PBMC-derived biomarker discovery. 3 Mapping the expression pattern of the genes identified through leukocyte-based microarray mining approaches in the clinical arena might help differentiate the patients who have varying disease severity. It is clear that confirmatory studies of these genes and their respective protein products are needed to determine the utility of using PBMC 
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to elucidate genes involved in incontinence-related disease. However, this provides a unique approach toward screening and elucidating novel biomarkers in disease via interrogation of the immune system vs the conventional approach of obtaining tissue directly from the affected organ. Additional studies are needed that encompass patient variation and disease expression in conjunction with comparison of gene expression differences, where possible obtained from the affected solid organ, to determine the reality of genes involved in disease.
In conclusion, PBMC are an easily accessible source of blood leukocytes that can provide a reporter function for solid organ disease. Furthermore, this approach may identify as of yet unknown genes that may be involved in the pathogenesis of diseases. These data suggest that PBMC can provide a reporter function for patients with incontinence and may serve as a diagnostic marker and/or monitor response to therapy and, as such, contribute to biomarker discovery and disease management in women's health.
